Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## UnitedHealthcare Step-Therapy Denials on Immune Checkpoint Inhibitors

When UnitedHealthcare denies Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, or Libtayo on step-therapy grounds under the Oncology Medication Clinical Coverage – UHC Commercial Medical Benefit Drug Policy (eff. 04/01/2026), the denial almost always reduces to one mechanic: the requested agent is classified as non-preferred for that specific tumor type and the prescriber has not satisfied the Preferred Product Criteria. UHC's policy is indication-specific — Keytruda Qlex is preferred in NSCLC but non-preferred in head and neck; Libtayo is preferred in cutaneous squamous cell while Keytruda, Opdivo, and Unloxcyt are non-preferred. A reviewer at OptumRx will reject a Libtayo request for HNSCC, or a Keytruda request for cSCC, on a pure formulary-tier basis regardless of NCCN Category 1 support.

The appeal must attack the Preferred Product Criteria, not the NCCN compendium. UHC concedes NCCN 1/2A/2B as medically necessary — that fight is already won. The denial is a non-medical necessity NQTL. To prevail, the attestation under UHC's policy must demonstrate (1) a documented history of intolerance, contraindication, or grade ≥3 immune-related adverse event to the preferred PD-1/PD-L1 agent for that indication, AND (2) physician attestation that the same toxicity would not be expected with the requested non-preferred agent. The second prong is where most appeals fail — boilerplate language about "different mechanism" will not survive Optum review. Cite the specific irAE (e.g., prior pembrolizumab-induced grade 3 pneumonitis), then distinguish based on Fc-engineering, dosing interval, or published rechallenge data.

Federal step-therapy override leverage applies for ERISA plans. Under 29 USC §1185d and CMS step-therapy guidance, UHC must grant an exception where the preferred drug is expected to be ineffective, has caused an adverse reaction, or where the patient is stable on the requested therapy. For Medicare Advantage members, 42 CFR §422.566 governs the organization determination and §422.568 sets the 72-hour expedited timeline when delay would jeopardize life or health — invoke expedited review explicitly for any active-treatment oncology denial. For ERISA commercial plans, 29 CFR §2560.503-1(h)(3)(iii) entitles you to the full claim file, internal Optum clinical criteria, and reviewer credentials within 30 days.

Pinto v. Aetna (10th Cir. 2014) is directly on point: where a plan invokes a coverage exclusion, the burden shifts to the plan to prove the exclusion applies. UHC bears the burden of showing the preferred agent is clinically appropriate for this patient — not the other way around.

Tactical tip: File the appeal through the OptumRx provider portal with the NCCN compendium citation, the PD-L1/TPS/CPS lab result, and a one-page table comparing irAE profiles of the preferred vs. requested agent. Simultaneously file a parallel complaint with your state DOI (or DMHC if California) citing NQTL parity and step-therapy override violation — UHC resolves dual-track appeals materially faster than single-channel internal appeals.